

Andreas Bockisch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/374969/publications.pdf>

Version: 2024-02-01

32
papers

2,133
citations

394421

19
h-index

395702

33
g-index

33
all docs

33
docs citations

33
times ranked

2391
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2611-2621.	2.5	2
2	The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 235-252.	0.7	20
3	Positron Emission Tomographyâ€“Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2024-2034.	1.6	176
4	Value of ¹⁸ Fâ€“FDG PET/MRI for the outcome of ¹⁸ Fâ€“FDG-guided facet block therapy in cervical facet syndrome: initial results. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 327-333.	1.8	15
5	Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT. <i>European Radiology</i> , 2017, 27, 4091-4099.	4.5	66
6	Diagnostic accuracy of 18Fâ€“FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma. <i>BMC Cancer</i> , 2017, 17, 887.	2.6	16
7	Discrepant salivary gland response after radioiodine and MIBG therapies. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 331-339.	0.7	7
8	High Level of Agreement Between Pretherapeutic ¹²⁴ I PET and Intratherapeutic ¹³¹ I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1339-1342.	5.0	39
9	Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trial of whole-body PET/MRI versus PET/CT. <i>European Journal of Radiology</i> , 2016, 85, 1941-1947.	2.6	50
10	Potential influence of Gadolinium contrast on image segmentation in MR-based attenuation correction with Dixon sequences in whole-body 18F-FDG PET/MR. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2016, 29, 301-308.	2.0	11
11	Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative 124I-NaI-PET/CT in patients with papillary thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1988-1994.	6.4	5
12	18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1646-1652.	6.4	16
13	Hybrid imaging of the bowel using PET/MR enterography: Feasibility and first results. <i>European Journal of Radiology</i> , 2016, 85, 414-421.	2.6	22
14	Imaging of differentiated thyroid carcinoma: 124I-PET/MRI may not be superior to 124I-PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1185-1186.	6.4	4
15	PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. <i>Theranostics</i> , 2015, 5, 1388-1401.	10.0	186
16	Integrated FDG PET/MR Imaging for the Assessment of Myocardial Salvage in Reperfused Acute Myocardial Infarction. <i>Radiology</i> , 2015, 276, 400-407.	7.3	37
17	Prognostic value of 18F-fluorodeoxyglucose PET-CT imaging in acute aortic syndromes: comparison with serological biomarkers of inflammation. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 1677-1685.	1.5	17
18	Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy 124I PET/CT imaging. <i>EJNMMI Physics</i> , 2014, 1, 100.	2.7	17

#	ARTICLE	IF	CITATIONS
19	The effect of radioiodine therapy after total thyroidectomy. <i>Nature Reviews Endocrinology</i> , 2013, 9, 511-512.	9.6	2
20	Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 48-56.	6.4	69
21	Matched pairs for radionuclide-based imaging and therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1-3.	6.4	19
22	Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 884-895.	6.4	59
23	The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2298-2306.	6.4	65
24	Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2267-2276.	6.4	61
25	The XbaI G>T Polymorphism of the Glucose Transporter 1 Gene Modulates 18F-FDG Uptake and Tumor Aggressiveness in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1191-1197.	5.0	23
26	Hybrid Imaging by SPECT/CT and PET/CT: Proven Outcomes in Cancer Imaging. <i>Seminars in Nuclear Medicine</i> , 2009, 39, 276-289.	4.6	130
27	Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 611-623.	6.4	89
28	Optimized ¹²⁴ I PET Dosimetry Protocol for Radioiodine Therapy of Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1017-1023.	5.0	135
29	Respiration artifacts in whole-body 18F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1429-1439.	6.4	56
30	Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2005, 46, 429-35.	5.0	60
31	Non- ¹⁸ F Small Cell Lung Cancer: Dual-Modality PET/CT in Preoperative Staging. <i>Radiology</i> , 2003, 229, 526-533.	7.3	525
32	Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1339-42.	5.0	130